Abbott Laboratories Corporation

Abbvie Inc.

Other

Abbott Gmbh & Co Kg

Irene I Drizin

Robert J Altenbach

William A Carroll

Huaqing Liu

Marlon D Cowart

James F Kerwin

Arthur Gomtsyan

John R Koenig

Richard J Perner

Michael D Meyer

Chih-hung Lee

Sean Colm Turner

Lawrence A Black

Guo Zhu Zheng

Michael E Kort

Erol K Bayburt

Robert G Schmidt

Mark W Holladay

Fatima Z Basha

Stanley DiDomenico

Brian D Wakefield

Henry Q Zhang

Tammie K White

Chen Zhao

Michael D Wendt

Kevin B Sippy

Karin Rosemarie Tietje

Suzanne A Lebold

Edmund L Lee

Lin Yi

Philip R Kym

George A Doherty

Andrew O Stewart

Pramila A Bhatia

James P Sullivan

Neil Wishart

Jorge D Brioni

Diane M Yamamoto

Robert J Gregg

Gin C Hsieh

Marie P Honore

Timothy A Esbenshade

David J Babinski

Arthur A Hancock

Konstantinos A Agrios

Yiyuan Chen

John K Pratt

Helmut Mack

Anthony Ralph Haight

Gregory A Gfesser

Jerome F Daanen

Kevin R Woller

Jimmie L Moore

Eric A Voight

Kathleen Mortell

Anurupa Shrestha

Qingwei Zhang

Kathryn J Hancock, Legal Representative

Weijiang Zhang

Rui Tang

Steven W Elmore

Michael J Kort

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, R, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar, n, R, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Lactam acetamides as calcium channel blockers

Macrocyclic benzofused pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions are described herein.

Macrocyclic benzofused pyrimidine derivatives

Heteroaryl-fused macrocyclic 2,4-diaminopyrimidine compounds of formula (I) wherein W, G, G, Aand Rare defined in the description, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Heteroaryl-fused macrocyclic pyrimidine derivatives

Macrocyclic pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Macrocyclic pyrimidine derivatives

The present application describes substituted pyrimidine compounds of formula (I) wherein X, A, R, R, R, R, R, R, R, R, R, p, q, r, v, and w are defined in the specification, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions.

Substituted pyrimidine derivatives

Amino heterocyclic linked pyrimidine derivatives

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X, X, X, X, X, R, R, R, R, R, R, Z, Zand L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar, Ar, L, L, n, R, R, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Compounds as calcium channel blockers

This invention discloses a method of treating pain by administering histamine Hreceptor ligands and compositions comprising the same.

Method for pain treatment

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X, X, X, X, X, R, R, R, R, R, R, Z, Z, and L are defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor

The isoquinoline compounds of formula (I)are VR1 antagonists that are useful in treating pain, inflammation, thermal hyperalgesia, urinary incontinence and bladder over activity. The 'R', 'Z' and &#x201c;L&#x201d; variables are defined in the disclosure and the &#x201c;X&#x201d; variables are defined as follows:

Compounds of formula (I)are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X, X, X, X, X, R, R, R, R, R, R, Z, Zand L are as defined in the description.

Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers

Pyrano, piperidino, and thiopyrano compounds and methods of use

Growing community of inventors

Wadsworth, IL, United States of America

Irene I Drizin